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The interaction of mutagenic Cr(VI) with red blood cells has been studied by ESR spectroscopy. Signals of two Cr(V) species are observed almost 
immediately after contacting red cells with chromate(V1) aqueous solution at pH 7.4. The signal at g, = 1.985, which decays within one hour, is 
attributed to a Cr(V) complex formed by glutathione due its reducing and chelating ability. The other signal at g, = 1.979, which is distinctly more 
persistent, may indicate that some immobilization of the formed Cr(V) ions takes place on the macromolecular cell components, e.g. glycoproteins. 
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1. INTRODUCTION 
Although chromium compounds are well recognized 
as potent inorganic mutagens or even carcinogens 
[I-S], the precise description of the active species as 
well as the mode of its action is still not available. It 
seems to be generally accepted that Cr(V1) is the initial 
oxidation state in the mutagenic pathway of this metal 
ion. It seems also to be chemically intelligible that the 
ultimate form bound to small cellular moieties like 
DNA or proteins is the Cr(II1) ion. It was shown, 
among others, that Cr(II1) ions may cross-link nucleic 
acids or condensate them very effectively [6-91. A 
number of works also indicated very clearly that the in- 
termediate oxidation state Cr(V), may play a critical 
role in the biochemic~ and chemical behaviour of 
chromium in the living systems [ 10-131. Cr(V) is a 
highly reactive species and most likely is easily 
transported into the cell organella. Many molecules 
present in the living system, both in the membranes and 
inside the cells, may act as reducing agents for Cr(V1) 
ions. The extensive work of Connett and Wetterhahn 
[ 141 indicated several possibilities for chromium(V1) 
reduction by biomolecules. One of the most important 
representatives of reducing biomolecules is the tripep- 
tide glutathione (y-Glu-Cys-Gly, GSH) which is a very 
abundant molecule in the living cell. Although the 
detailed mechanism of the reduction of Cr(V1) to Cr(V) 
in the presence of GSH is not yet available 
[13,14,16,17], it is evident that some relatively long- 
lived species of Cr(V) are produced. Cr(V) ions can be 
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stabilized very effectively by several natural ligands like 
e.g. glucose or other sugars [15,18]. In blood cells the 
interaction between GSH and chromium ions seems to 
be very likely (see e.g. [16]) and the direct interaction 
between the GSH and Cr(V1) may be an important 
source of Cr(V) ions in these cells. In order to clarify 
the problem of chromium reduction in the cell, we have 
performed the studies on the behaviour of Cr(V1) in the 
blood cells using the ESR technique and the results are 
presented in this communication. 
2. EXPERIMENTAL 
Blood, with EDTA as anticoagulant, of normal adult was used. 
Plasma and buffy coat were carefully removed by aspiration after 
centrifugation. Red blood cells were washed three times in the buffer 
prior to use. Equal volumes of packed red blood cells and buffer con- 
taining 10 mM Cr(VI) as chromate were mixed and immediately 
transferred into a flat ESR cell. In order to block GSH, N- 
ethylmaleimide (NEM) was added to the red blood cell suspension 
[I91 before addition of Cr(V1) ions (final concentration ranging from 
0.5 to 1.5 mM). Lysates were made by freezing-thawing under 
nitrogen in order to avoid oxidation by air. The ESR spectra were 
recorded at room temperature on a Bruker 220 D instrument. The 
microwave frequency was 9.4 GHz, the radiation power 10 mW and 
the modulation amplitude 0.4-4.0 G. 
3. RESULTS AND DISCUSSION 
The interaction of Cr(V1) with red blood cells results 
in two ESR signals (fig. 1) already several minutes after 
mixing chromate with the red cells. The narrow ESR 
signal at go = 1.985 decays within one hour. The other 
one at g, = 1.979 is distinctly broader and vanishes 
within one day. In the samples treated with N- 
ethylmaleimide only one spectrum was observed at go = 
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Fig.1. ESR spectra of Cr(V) species formed by interaction of 
chromate (10 mM) with red blood cells as a function of time (min). 
1.979. In the latter samples the GSH reduction ability 
is inhibited totally by added NEM (due to covalent 
blocking of the GSH molecule). Thus, the signal at 
g, = 1.985 can be attributed to the Cr(V)-GSH system. 
A further support to this assignment derives from the 
fact that equimolar (2.5 mM) aqueous solutions of 
GSH and chromate at pH 7.4 yield only the narrow 
spectrum at go = 1.985 (fig.2b), which has also been 
described previously [ 131. This species also decays 
rapidly yielding Cr(II1) as the final reduction product. 
Furthermore, the addition of GSH to the sample con- 
taining red blood cells and Cr(V1) leads to a distinct in- 
crease of the signal at go = 1.985. This unequivocally 
Fig.2 ESR spectra of Cr(V) species formed: (a) by interaction of 
chromate (10 mM) with red blood cells after 64 min (cf. fig.1); (b) by 
interaction of chromate (2.5 mM) with GSH in 1: 1 molar ratio. 
Spectrum c is obtained by addition of the spectra a and b. 
indicates that the GSH molecule is a reducing agent of 
chromium(V1) in the cell but not the only one. GSH (or 
its oxidized form) is also a chelating agent for Cr(V) 
ions produced [ 12,131 although the formed species easi- 
ly decay towards Cr(II1) complexes. It is very likely that 
Cr(V) ions obtained by the reduction of chromate with 
GSH are transferred to the chelating agents more effec- 
tively than GSH itself or that GSH reduces Cr(VI) ions 
bound to other molecules. The experiment shown in 
fig.3a clearly suggests uch a possibility. The addition 
of a sugar ligand to the chromate-GSH solution results 
almost immediately in the formation of the Cr(V) com- 
plexes with the sugar molecules and these latter species 
are distinctly more stable than those with glufathione. 
The reduction ability of sugar molecules is much less ef- 
fective since within the same time no Cr(V) ESR signal 
is observed in the solutions containing only chromate 
and sugar, The more detailed description of the latter 
experiments will be published elsewhere [20]. 
The ESR spectrum at go = 1.979 indicates very clear- 
ly that there are other reducing agents too, in the red 
blood cells. The broader shape of the signal may in- 
dicate that some immobilization of the formed Cr(V) 
ions takes place on macromolecular components, e.g. 
glycoproteins, as shown by the comparison with the 
spectrum of a Cr(V) species bound to a polymeric 
matrix (fig.3b). These components can more effectively 
stabilize this oxidation state. Cr(V1) reduction in the 
blood plasma which does not contain reduced 
glutathione results in the spectrum centered at g, = 
1.979. This experiment again provides evidence of the 
direct involvement of GSH in the reduction of 
chromate inside the cell, and also supports the presence 
of other efficient Cr(V1) reductants (possibly enzymes) 
in the living systems. The ESR spectrum of Cr(V1) add- 
ed to the lysed cells is identical to those obtained for the 
intact red blood cells. This result substantiates the fact 
that chromate ions may easily enter the cells by crossing 
the membrane and then undergo the reduction pro- 
cesses as discussed above. 
10 G 
J a 
i” 
b 
Fig.3. ESR spectra of CrfV) species obtained a few minutes after 
interaction of chromate with (a) D-mannose or (b) polygalacturonic 
acid at pH 7.4 in the presence of GSH. Spectrum a was recorded in 
solution, spectrum b was recorded in the solid state. 
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4. CONCLUSIONS 
Chromium(VI) ions penetrate red blood cells 
undergoing reduction to Cr(V) intermediates and fur- 
ther to Cr(III) ions. Glutathione is an important in- 
tracellular reducing agent for CrfVI) ions. It does not, 
however, stabilize effectively the Cr(V) species formed. 
GSH, however, is not the only reductant inside the cell. 
Sugar containing molecules could be competitive in 
both reduction of Cr(VI) and stabilization of the Cr(V) 
intermediate. It is thus likely that part of the chromium 
ions which undergo the reduction process with GSH is 
already bound to the other ligands which are more ef- 
fective in the stabilization of the (+ 5) oxidation state 
than glutathione itself. The further .reduction of the 
Cr(V) ion anchored to a biomolecule to Cr(II1) can also 
modify the chemical structure of the ligand, altering the 
primary function of the natural system. 
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